PBAC Public Summary Documents – September 2025

Page last updated: 24 December 2025

Public Summary Documents relating to the September 2025 PBAC meeting.

• Dapagliflozin: Tablet 10 mg; Forxiga® – September 2025
• Osimertinib: Tablet 40 mg, Tablet 80 mg; Tagrisso® – September 2025

The following Public Summary Documents have been updated:

March 2025 PBAC Meeting

• Mogamulizumab; Solution concentrate for I.V. infusion 20 mg in 5 mL; Poteligeo®
• Zolbetuximab; Powder for I.V. infusion 100 mg (20 mg per mL); Vyloy®

July 2025 PBAC Meeting

• Vanzacaftor with tezacaftor and with deutivacaftor; Tablet containing 4 mg vanzacaftor with 20 mg tezacaftor and with 50 mg deutivacaftor, Tablet containing 10 mg vanzacaftor with 50 mg tezacaftor and with 125 mg deutivacaftor; Alyftrek®